CN1943651A - Medicine composition for treating gout - Google Patents
Medicine composition for treating gout Download PDFInfo
- Publication number
- CN1943651A CN1943651A CN 200610022085 CN200610022085A CN1943651A CN 1943651 A CN1943651 A CN 1943651A CN 200610022085 CN200610022085 CN 200610022085 CN 200610022085 A CN200610022085 A CN 200610022085A CN 1943651 A CN1943651 A CN 1943651A
- Authority
- CN
- China
- Prior art keywords
- gram
- gout
- medicine
- naproxen
- ketoprofen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 201000005569 Gout Diseases 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims description 13
- 229940079593 drug Drugs 0.000 title claims description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 16
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960002009 naproxen Drugs 0.000 claims abstract description 9
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 239000000284 extract Substances 0.000 claims abstract description 8
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960000991 ketoprofen Drugs 0.000 claims abstract description 8
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 claims abstract description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 8
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 claims description 7
- 229940120889 dipyrone Drugs 0.000 claims description 7
- 229960002800 prednisolone acetate Drugs 0.000 claims description 7
- 229930003270 Vitamin B Natural products 0.000 claims description 6
- 235000019156 vitamin B Nutrition 0.000 claims description 6
- 239000011720 vitamin B Substances 0.000 claims description 6
- 230000003203 everyday effect Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 7
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 3
- 230000000295 complement effect Effects 0.000 abstract description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract description 2
- 235000019158 vitamin B6 Nutrition 0.000 abstract description 2
- 239000011726 vitamin B6 Substances 0.000 abstract description 2
- 229940011671 vitamin b6 Drugs 0.000 abstract description 2
- 241000340661 Stauntonia chinensis Species 0.000 abstract 1
- MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 abstract 1
- 229960001407 sodium bicarbonate Drugs 0.000 abstract 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 5
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 4
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 4
- 229960003459 allopurinol Drugs 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229960002529 benzbromarone Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229940116269 uric acid Drugs 0.000 description 4
- 229960002708 antigout preparations Drugs 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000026816 acute arthritis Diseases 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010061172 Gastrointestinal injury Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010018873 Haemoconcentration Diseases 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- -1 correctives Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 150000003118 prednisones Chemical class 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A pharmaceutical composition for treating gout comprises analgin, ketoprofen, dry extract of Stauntonia chinensis, prednisone acetate, naproxen, vitamin B6 and sodium bicarbonate. The formula is reasonable in design, has the characteristics of remarkable curative effect on gout, quick response, convenience in taking and difficulty in rebounding after stopping taking the medicine, has a complementary effect on a plurality of components of the formula, has small damage to a body, is a cheap and easily-obtained common medicine which is clinically applied in a large amount for a long time, is safe and effective, and has controllable quality.
Description
Technical field
The present invention relates to a kind of medicine of medicine composite for curing gout, particularly relate to a kind of Chinese and western medicinal composition for the treatment of gout.
Background technology
Gout is a kind of very obstinate disease, is a kind of frequently-occurring disease in recent years, and is closely related with the raising of people's living standard.Goat all can take place at any age, was a kind of syndrome that is caused by purine substance metabolism disorder in the body.The acute arthritis, merging gout calculus, the blood uric acid concentration that have outbreak repeatedly clinically increase features such as joint deformity and nephropathy.
For many years, the antigout drug kind on China's medical market mainly is the Western medicine of several treatment gouts seldom, and the antipodagric prescription of Chinese medicine is immature substantially, and drug effect is poor.Since nearly more than ten years, market does not have new better anti-gout drugs to develop, and clinical application is taken on the leading role by probenecid, colchicine, allopurinol, these four kinds of medicines of benzbromarone always.This external NSAID (non-steroidal anti-inflammatory drug) (NSAIDs) is as indomethacin, Phenylbutazone, piroxicam, naproxen, ibuprofen etc.; Glucocorticoids is handled to the ill as works such as prednisones.
Probenecid has another name called benemid, just at gout intermission control blood uric acid content, acute gout is not had therapeutic effect; Colchicine is a kind of alkaloid that extracts in the liliaceous plant, is alleviating pain when the gout acute attack, but invalid to chronic gout, owing to be from plant, to extract, thereby output is restricted; Allopurinol has another name called allopurinol, it is the medicine that the only so far level that can effectively reduce uricopoiesis, reduction blood and urine uric acid is treated primary gout, but its toxic and side effects mainly is bone marrow depression, its pancytopenia that causes is relevant with dosage, in addition, the haemoconcentration of allopurinol depends on also whether renal function is sound; Benzbromarone has another name called Benzbromarone, narcaricin etc., is strong acidum ethacrynicum medicine, and is existing for many years in European extensive use, toxic action is slight, do not influence hepatic and renal function, rare erythra, heating, but intestines and stomach reaction, renal colic can be arranged and excite the acute arthritis outbreak.Market sale in recent years is better, is subjected to clinical welcome, but the price of benzbromarone is more expensive, particularly imported medicine and gun propellant separated loading charge.
Be these familiar faces basically on the anti-gout drugs market, aspects such as curative effect price side effect when are also not fully up to expectations, all bounce-backs at short notice of serum uric acid level after the drug withdrawal.Therefore the present invention proposes a kind of little to physical impairment, gout had the pharmaceutical composition that is difficult for bounce-back after better curative effect and the drug withdrawal treat gout.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of gout, prescription is reasonable in design, and medicament sources is the general medicine cheap and easy to get of clinical long-term extensive application, and is safe and effective, quality controllable.
The object of the present invention is achieved like this: prescription (in three times single medication amount every day) and optimum ratio are as follows
Component prescription optimum ratio
Dipyrone 0.1-2.0 gram 0.4-1.2 gram
Vitamin B
60.05-2.0 gram 0.1-1.2 gram
Ketoprofen 0.1-1.2 gram 0.4-1.0 gram
Caulis et folium stauntoniae dry extract 0.4-2.4 gram 0.4-2.0 gram
Prednisolone acetate 0.05-1.0 gram 0.1-0.4 gram
Naproxen 0.05-1.0 gram 0.1-0.8 gram
Sodium bicarbonate 0.1-2.0 gram 0.2-1.2 gram
Various compositions in this prescription all have extensive sale on market, wherein dipyrone is an antipyretic analgesic, can be used for headache, migraine, myalgia, arthralgia etc., and stronger anti rheumatism action is also arranged.Vitamin B
6Can participate in hormone and erythrocytic synthetic, also be that protein metabolism, nervous system and immune system running institute are essential, is usually used in anemia, depression, insomnia, dysbasia, scytitis.Ketoprofen is used for various arthritis, rheumatoid arthritis, osteoarthritis, gouty arthritis etc.The Caulis et folium stauntoniae dry extract is used for wind-expelling pain-stopping, relaxing muscles and tendons and activating QI and blood in the collateral, ailment said due to cold or exposure resistance network type, trigeminal neuralgia, sciatica, rheumatic arthritis.Prednisolone acetate has antiinflammatory, antiallergic, rheumatism immunosuppressive action, be used for anaphylaxis and autoimmune inflammation disease, anaphylactic diseases such as knot hoof tissue disease, systemic lupus erythematosus (sle), serious bronchial asthma, dermatomyositis, vasculitis, acute leukemia, malignant lymphoma and be applicable to disease of other adrenal cortex hormones drug etc.Naproxen belongs to nonsteroidal anti-inflammatory analgetic, can suppress the synthetic of prostaglandin and the effect of performance anti-inflammatory and antalgic is used for alleviating slightly to moderate pain, as arthralgia, neuralgia, myalgia, headache etc.Sodium bicarbonate is used for alkalized urine, promotes urate excretion, hyperchlorhydria, antiinflammatory etc.Especially remarkable according to this medicine composition gained medicine to the curative effect of gout disease.
Several compositions of this medicine composition have complementary action, so very little to the human injury.Dipyrone, ketoprofen, prednisolone acetate, these four kinds of medicines of naproxen all have injury to gastrointestinal tract, skin, Liver and kidney, so this product is added sodium bicarbonate and vitamin B
6Just can alleviate effectively and the injury of treatment stomach and liver, kidney;
The acceptable accessories that pharmaceutical composition of the present invention comprised can be pharmaceutical carrier, excipient and other additive that conventional formulation is used.If necessary, pharmaceutical composition of the present invention also can comprise other active component.Pharmaceutical composition of the present invention can the dosage unit preparations oral administration, but be suitable for the form that orally uses tablet, capsule dispersed powders or granule can be arranged.Can be by any known method preparation in the prior art, such compositions can comprise one or more reagent that is selected from sweeting agent, correctives, coloring agent and antiseptic, so that pharmaceutically attractive in appearance and agreeable to the taste preparation to be provided.Tablet comprises active component and is suitable for the nontoxic pharmaceutically acceptable excipient of tablet manufacturing.These excipient for example can be inert diluents, as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate, cellulose etc.; Granulating agent and disintegrating agent are as corn starch or alginic acid etc.; Binding agent is as starch, gelatin or arabic gum etc.; Lubricant is as magnesium stearate, stearic acid or Pulvis Talci etc.Tablet can be coating not, perhaps can adopt known technology to carry out coating.Oral formulations can be a hard gelatin capsule, and wherein, active component and inert solid diluent for example calcium carbonate, calcium phosphate or starch are mixed, and can add sweeting agent and correctives so that agreeable to the taste oral formulations to be provided.Can add antioxidant in these compositionss such as ascorbic acid carries out anticorrosion.But dispersed powders is that active component is mixed with dispersant or wetting agent, suspending agent and one or more antiseptic, is suitable for preparing suitable water slurry by adding water.But also can comprise other excipient such as sweeting agent, correctives and coloring agent in the dispersed powders.
The specific embodiment
1 tablet formulation and method for making (making 1000):
Dipyrone 100 grams
Vitamin B
640 grams
Ketoprofen 100 grams
Caulis et folium stauntoniae dry extract 320 grams
Prednisolone acetate 20 grams
Naproxen 40 grams
Sodium bicarbonate 200 grams
Calcium carbonate is an amount of
Pulvis Talci is an amount of
10% starch slurry is an amount of
Low-substituted hydroxypropyl cellulose is an amount of
Above-mentioned raw materials is worn into fine powder, cross 100 mesh sieves; Adopt the equivalent method of progressively increasing to mix supplementary material adjuvant (calcium carbonate, low-substituted hydroxypropyl cellulose), cross 80 mesh sieves 3-4 time, make abundant mixing; In mixture, add 10% starch slurry system soft material, cross 24 order system wet granulars, dry in 55-60 ℃ of ventilation drying baker; Dried particles is added Pulvis Talci behind 20 order granulate, the scrobicula stamping of usefulness diameter 6.0mm promptly.Usage: three times on the one, a 4-6 sheet.
2, capsule formula and method for making (making 1000)
It is manual promptly encapsulated to get dipyrone 400 gram, vitamin B6 150 grams, ketoprofen 500 grams, Caulis et folium stauntoniae dry extract 1000 grams, prednisolone acetate 100 grams, naproxen 400 grams, sodium bicarbonate 150 grams, an amount of mixing of diluent starch.Usage: three times on the one, a 2-3 grain.
Clinical efficacy data and model case:
1. the Yan, the man, 29 years old, fat, the company clerk.Because it is many that friend treats with courtesy, long-term eating and drinking too much at one meal, last Jul feels that the left ankle joint becomes swollen again after sore, pain back unbearably is gout to hospital diagnosis.Take this medicine after hospitalize is invalid, through three day time, redness and swelling of joints, pain symptom disappeared.
2. Liu, the woman 43 years old, is engaged in artistic creation work.Because life is irregular with dietary habit, got gout in last year.Took this medicine after hospitalize is invalid 2 days, redness and swelling of joints, pain symptom disappear.
3. Zhu, man, 56 years old, self-employed entrepreneurs.Because of family's affluence, plenty of meat and fish has the beer everyday, and is fat, suffered from gout several years ago, because there is not what good Therapeutic Method and medicine, caused joint deformity afterwards, be unable to leave the bed, can not walk, after take this medicine after 7 days, the state of an illness is clearly better, the walking of leaving the bed.
Claims (2)
1. pharmaceutical composition for the treatment of gout is characterized in that said composition comprises following component (in three times single medication amount every day) and constitutes:
Dipyrone 0.1-2.0 gram
Vitamin B
60.05-2.0 gram
Ketoprofen 0.1-1.2 gram
Caulis et folium stauntoniae dry extract 0.4-2.4 gram
Prednisolone acetate 0.05-1.0 gram
Naproxen 0.05-1.0 gram
Sodium bicarbonate 0.1-2.0 gram
2. pharmaceutical composition according to claim 1 is characterized in that said composition made by following component (in three times single medication amount every day):
Dipyrone 0.4-1.2 gram
Vitamin B
60.1-1.2 gram
Ketoprofen 0.4-1.0 gram
Caulis et folium stauntoniae dry extract 0.4-2.0 gram
Prednisolone acetate 0.1-0.4 gram
Naproxen 0.1-0.8 gram
Sodium bicarbonate 0.2-1.2 gram
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100220859A CN1943651B (en) | 2006-10-20 | 2006-10-20 | A medicinal composition for treating gout |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100220859A CN1943651B (en) | 2006-10-20 | 2006-10-20 | A medicinal composition for treating gout |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1943651A true CN1943651A (en) | 2007-04-11 |
| CN1943651B CN1943651B (en) | 2010-09-01 |
Family
ID=38043445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006100220859A Expired - Fee Related CN1943651B (en) | 2006-10-20 | 2006-10-20 | A medicinal composition for treating gout |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1943651B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108096275A (en) * | 2018-01-22 | 2018-06-01 | 马艳红 | A kind of Western medicine compound for treating gout |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100457143C (en) * | 2004-11-29 | 2009-02-04 | 成都华西天然药物有限公司 | Medication for treating gout |
| CN1806797A (en) * | 2005-01-19 | 2006-07-26 | 周艳 | Ketoprofen medicinal composition for treating rheumatoid arthritis and preparation method thereof |
-
2006
- 2006-10-20 CN CN2006100220859A patent/CN1943651B/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108096275A (en) * | 2018-01-22 | 2018-06-01 | 马艳红 | A kind of Western medicine compound for treating gout |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1943651B (en) | 2010-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005068060A (en) | Pharmaceutical composition containing lactoferrin and method for producing processed food containing lactoferrin | |
| Kaushik et al. | Therapeutic potentials of cow derived products-a review | |
| JP2004513095A (en) | Disease relief preparation | |
| CN102525974A (en) | Meloxicam tablets for dogs and cats and preparation method for meloxicam tablets | |
| CN109393147A (en) | A kind of composition and preparation method thereof for safeguarding dog cat urinary tract health | |
| JP5679721B2 (en) | Pharmaceutical composition containing Kampo extract | |
| CA2376008A1 (en) | Combination of glucosamine with herbal extracts of tripterygium, ligustrum and erycibe | |
| JPH11130686A (en) | Prevention and curing of obesity, and anti-obesity agent | |
| CN1943651B (en) | A medicinal composition for treating gout | |
| CN103705479B (en) | A kind of pet Meloxicam sustained release tablets and preparation method thereof | |
| CN111265599A (en) | Application of lycopene and grape seed composition in preparation of medicine for treating arthritis | |
| CN115068425A (en) | Method for producing phenylephrine resinate particles, phenylephrine resinate particles and use thereof in medicaments | |
| Haque et al. | Anti-inflammatory activity of d-pinitol possibly through inhibiting COX-2 enzyme: in vivo and in silico studies | |
| CN106038566B (en) | A kind of pharmaceutical composition and its application for curing gastric cancer | |
| CN105832732A (en) | Pharmaceutical composition for treatment of gastric cancer and application of pharmaceutical composition for treatment of gastric cancer | |
| CN100411650C (en) | A compound capsule for treating Bi syndrome | |
| CN101623411A (en) | Chinese medicament for resisting bacteria and diminishing inflammation, clearing away heat and toxic material, and removing blood stasis and relieving pain | |
| CN116265027B (en) | A Chinese medicinal compound preparation containing Tripterygium for treating inflammatory dermatoses | |
| CN108785681A (en) | A kind of compound antipyretic antalgic anti-inflammatory agent composite preparation and its application for animals | |
| CN115607588B (en) | Anti-gout apiary extract and non-bestatin pharmaceutical composition for treating both symptoms and root causes and application thereof | |
| CN103893512B (en) | A kind of Chinese medicine composition for treating urarthritis | |
| CN1452983A (en) | Delayed-releasing compound diclofenac sodium prepn | |
| JP2014055187A (en) | Oral solid composition reduced in irritation to digestive tract | |
| JP5676834B2 (en) | Oral solid composition with reduced irritation to the gastrointestinal tract | |
| CN1943617A (en) | Qiwei blood disease tablet, capsule and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100901 Termination date: 20111020 |